


make the necessary change in application number and filing date for the instant application. A copy of the notice to comply is enclosed.

Should the Office feel that telephonic communication with the applicants' representative would further the prosecution of the instant application, the Examiner is invited to telephone the undersigned.

No fees are believed due with this paper, but the Commissioner is hereby authorized to charge any fees which may be required, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,



Hesna J. Pfeiffer
Attorney for Applicant
Reg. No. 22,640

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6940
20876 cont seq submission

Enc: copy of the notice to comply

Date: July 18, 2001

In the specification:

Replace the paragraph beginning at page 4, line 23 with the following rewritten paragraph:

-- Figure 1 shows the nucleotide sequence of an antisense RNA to *E. coli lepB* mRNA, expressed from the DNA insert in plasmid pJB37 (SEQ ID NO: 3).

Figure 2 shows the nucleotide sequence of an antisense RNA to *E. coli viaA* mRNA, expressed from the DNA insert in plasmid Pjb53 (SEQ ID NO: 4).

Figure 3 shows the nucleotide sequence of a 714 nucleotide *PstI-HindIII* fragment of the *E. coli viaA* gene cloned in pJB53 (SEQ ID NO: 5).

Figure 4 shows the nucleotide sequence of an antisense RNA to *E. coli ddlB* mRNA, expressed from the DNA insert in plasmid pJB57 (SEQ ID NO: 6).

Figure 5 shows the nucleotide sequence of an antisense RNA to *orf1* of the *E. coli ampG* operon, expressed from the DNA insert in plasmid pJB59 (SEQ ID NO: 7).--

In the specification:


Replace the paragraph beginning at page 6, line 4 with the following rewritten paragraph:

--Figure 11 shows the nucleotide sequence of an 836 nucleotide *PstI/HindIII* fragment of the *E. coli secA* gene cloned in pJB3 (SEQ ID NO: 8).

Figure 12 shows the nucleotide sequence of an antisense RNA complementary to *E. coli secA* mRNA (SEQ ID NO: 9).--

Dated this 20th day of July 2001.

Respectfully submitted,



DANA L. TANGREN
Attorney for Applicant
Registration No. 37,246


WORKMAN, NYDEGGER & SEELEY
1000 Eagle Gate Tower
60 East South Temple
Salt Lake City, Utah 84111
Telephone: (801) 533-9800
Facsimile: (801) 321-8864

DLT:dfw

G:\DATA\WPDOCS3\DFW\DLT\URQUHART\010719TRANSREQUEST_50_3.DOC

Respectfully submitted,
KENYON & KENYON

Dated: June 15, 2001

By: 
Siu K. Lo
Reg. No. 46,877

One Broadway
New York, N.Y. 10004
(212) 908-6018

FOR FILING - 9/16/2001

09/80088

RECEIVED

NOV 13 2001

instant application. A paper copy of the substitute Sequence Listing is attached herewith.

TECH CENTER 1600/2900

Accordingly, no additional submissions or statements are believed to be necessary.

Applicants submit that the present application is ready for examination on the merits and early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618



22850

Daniel J. Pereira, Ph.D.
Registration No. 45,518

(703) 413-3000
Fax #: (703) 413-2220